References
17
Borges A, Saavedra MJ, Simões M (2015) Insights on antimicrobial resistance, biofilms and the
use of phytochemicals as new antimicrobial agents. Curr Med Chem 22 (21):2590–2614
Bottegoni G, Cavalli A (2017) Computational methods in multitarget drug discovery. In: Decker M
(ed) Design of hybrid molecules for drug development. Elsevier, Amsterdam, pp 239–258
Breijyeh Z, Jubeh B, Karaman R (2020) Resistance of Gram-negative bacteria to current antibacterial
agents and approaches to resolve it. Molecules 25 (6):1340–1362
Bremner JB (2017) Molecular design of potential triple-action antibacterial agents and related
pro-drugs. SWU Sci J 33 (1):1–19
Brötz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr
Opin Pharmacol 8 (5):564–573
Brown ED, Wright GD (2016) Antibacterial drug discovery in the resistance era. Nature 529:336–
343
Butler MS, Blaskovich MA, Cooper MA (2017) Antibiotics in the clinical pipeline at the end of
2015. J Antibiot (Tokyo) 70 (1):3–24
Butler MS, Paterson DL (2020) Antibiotics in the clinical pipeline in October 2019. J Antibiot
(Tokyo) 73 (6):329–364
Carvalho G, Forestier C, Mathias J-D (2019) Antibiotic resilience: a necessary concept to
complement antibiotic resistance? Proc R Soc B 286:20192408
CDC (2019) Antibiotic threats in the United States, 2019. Centers for Disease Control and
Prevention, Atlanta. https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed 2 Mar
2020
Chen L, Todd R, Kiehlbauch J et al. (2017) Notes from the field: Pan-resistant New Delhi metallobeta-lactamase-producing Klebsiella pneumoniae-Washoe County, Nevada, 2016. MMWR Morb
Mortal Wkly Rep 66: 33
Cooper MA (2018) Approaches to combat drug-resistant pathogens. Paper presented at the RACI
Organic Division National Conference Organic 18, University of Western Australia, Perth, 2–6
Dec 2018
Dixit R, Suseela MR (2013) Cyanobacteria: Potential candidates for drug discovery. Antonie van
Leeuwenhoek 103 (5):947–961
Farha MA, Brown ED (2019) Drug repurposing for antimicrobial discovery. Nat Microbiol 4
(4):565–577
Fridman O, Goldberg A, Ronin I et al. (2014) Optimization of lag time underlies antibiotic tolerance
in evolved bacterial populations. Nat 513:418–421
Gadakh B, Van Aerschot A (2015) Renaissance in antibiotic discovery: some novel approaches for
finding drugs to treat bad bugs. Curr Med Chem 22 (18):2140–2158
Gajdács M (2019) The concept of an ideal antibiotic: Implications for drug design. Molecules
24:892
Garcia-Gutierrez E, Mayer MJ, Cotter PD et al. (2019) Gut microbiota as a source of novel
antimicrobials. Gut Microbes 10 (1):1–21
Gilbert N (2018) One step ahead. Old drugs and new tricks are helping to restock the antibacterial
armoury. Nature 555: 55–57
Gonzales PR, Pesesky MW, Bouley R et al. (2015) Synergistic, collaterally sensitive β-lactam
combinations suppress resistance in MRSA. Nat Chem Biol 11 (11):855–861
Gorityala BK, Guchhait G, Goswami S et al. (2016) Hybrid antibiotic overcomes resistance in
P. aeruginosa by enhancing outer membrane penetration and reducing efflux. J Med Chem 59
(18):8441–8455
Gray DA, Wenzel M (2020) Multitarget approaches against multiresistant superbugs. ACS Infect
Dis 6:1346–1365
Hanessian S, Saavedra OM, Vilchis-Reyes MA et al. (2014) Synthesis, broad spectrum antibacterial
activity, and X-ray co-crystal structure of the decoding bacterial ribosomal A-site with 4 -deoxy4 -fluoro neomycin analogs. Chem Sci 5 (12):4621–4632
17
Borges A, Saavedra MJ, Simões M (2015) Insights on antimicrobial resistance, biofilms and the
use of phytochemicals as new antimicrobial agents. Curr Med Chem 22 (21):2590–2614
Bottegoni G, Cavalli A (2017) Computational methods in multitarget drug discovery. In: Decker M
(ed) Design of hybrid molecules for drug development. Elsevier, Amsterdam, pp 239–258
Breijyeh Z, Jubeh B, Karaman R (2020) Resistance of Gram-negative bacteria to current antibacterial
agents and approaches to resolve it. Molecules 25 (6):1340–1362
Bremner JB (2017) Molecular design of potential triple-action antibacterial agents and related
pro-drugs. SWU Sci J 33 (1):1–19
Brötz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr
Opin Pharmacol 8 (5):564–573
Brown ED, Wright GD (2016) Antibacterial drug discovery in the resistance era. Nature 529:336–
343
Butler MS, Blaskovich MA, Cooper MA (2017) Antibiotics in the clinical pipeline at the end of
2015. J Antibiot (Tokyo) 70 (1):3–24
Butler MS, Paterson DL (2020) Antibiotics in the clinical pipeline in October 2019. J Antibiot
(Tokyo) 73 (6):329–364
Carvalho G, Forestier C, Mathias J-D (2019) Antibiotic resilience: a necessary concept to
complement antibiotic resistance? Proc R Soc B 286:20192408
CDC (2019) Antibiotic threats in the United States, 2019. Centers for Disease Control and
Prevention, Atlanta. https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed 2 Mar
2020
Chen L, Todd R, Kiehlbauch J et al. (2017) Notes from the field: Pan-resistant New Delhi metallobeta-lactamase-producing Klebsiella pneumoniae-Washoe County, Nevada, 2016. MMWR Morb
Mortal Wkly Rep 66: 33
Cooper MA (2018) Approaches to combat drug-resistant pathogens. Paper presented at the RACI
Organic Division National Conference Organic 18, University of Western Australia, Perth, 2–6
Dec 2018
Dixit R, Suseela MR (2013) Cyanobacteria: Potential candidates for drug discovery. Antonie van
Leeuwenhoek 103 (5):947–961
Farha MA, Brown ED (2019) Drug repurposing for antimicrobial discovery. Nat Microbiol 4
(4):565–577
Fridman O, Goldberg A, Ronin I et al. (2014) Optimization of lag time underlies antibiotic tolerance
in evolved bacterial populations. Nat 513:418–421
Gadakh B, Van Aerschot A (2015) Renaissance in antibiotic discovery: some novel approaches for
finding drugs to treat bad bugs. Curr Med Chem 22 (18):2140–2158
Gajdács M (2019) The concept of an ideal antibiotic: Implications for drug design. Molecules
24:892
Garcia-Gutierrez E, Mayer MJ, Cotter PD et al. (2019) Gut microbiota as a source of novel
antimicrobials. Gut Microbes 10 (1):1–21
Gilbert N (2018) One step ahead. Old drugs and new tricks are helping to restock the antibacterial
armoury. Nature 555: 55–57
Gonzales PR, Pesesky MW, Bouley R et al. (2015) Synergistic, collaterally sensitive β-lactam
combinations suppress resistance in MRSA. Nat Chem Biol 11 (11):855–861
Gorityala BK, Guchhait G, Goswami S et al. (2016) Hybrid antibiotic overcomes resistance in
P. aeruginosa by enhancing outer membrane penetration and reducing efflux. J Med Chem 59
(18):8441–8455
Gray DA, Wenzel M (2020) Multitarget approaches against multiresistant superbugs. ACS Infect
Dis 6:1346–1365
Hanessian S, Saavedra OM, Vilchis-Reyes MA et al. (2014) Synthesis, broad spectrum antibacterial
activity, and X-ray co-crystal structure of the decoding bacterial ribosomal A-site with 4 -deoxy4 -fluoro neomycin analogs. Chem Sci 5 (12):4621–4632